1. Rituximab Therapy for Epstein-Barr Virus–Related Chronic Hepatitis Following Living Donor Kidney Transplantation 
Kazuhide Ohta, MD, PhD, Masaki Shimizu, MD, PhD, Akiko Nakai, MD, Tomoko Toma, MD, PhD, Yoshihito Kasahara, MD, PhD, Chihiro Arii, MS, Akihiro Yachie, MD, PhD, Takeshi Kawamura, MD, PhD, Atsushi Aikawa, MD, PhD, Akira Hasegawa, MD, PhD, Kazutaka Sato, MD, PhD, Hitoshi Yokoyama, MD, PhD, Isao Ishikawa, MD, PhD, Shoichi Koizumi, MD, PhD 
American Journal of Kidney Diseases 
Volume 48, Issue 6, Pages (December 2006)
DOI: /j.ajkd
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

2. Fig 1
Hematoxylin and eosin staining of the liver biopsy specimen (A) before and (B) after rituximab treatment. Immunohistochemistry shows (C) CD3+ T cells and (D) CD20+ B cells. (E) EBV-infected cells were detected by means of EBER-1 in situ hybridization.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

3. Fig 2 Rituximab therapy and clinical course.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions